Gaixia Liu

Gaixia Liu

Auto-generated profile, based on publicly available information

Gaixia Liu

Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2023 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
LZLei Zhang
Lei Zhang
CHChenhao Hu
Chenhao Hu
ZZZhe Zhang
Zhe Zhang
LRLiu ruihan
Liu ruihan
GLGaixia Liu
Gaixia Liu
FSFeiyu Shi
Feiyu Shi

25 July 2024 in iScience
Verified
Journal Article
Open access
GLGaixia Liu
Gaixia Liu
CHChenhao Hu
Chenhao Hu
JWJiangpeng Wei
Jiangpeng Wei
QLQixin Li
Qixin Li
JZJiaqi Zhang
Jiaqi Zhang
FSFeiyu Shi
Feiyu Shi
The vermiform appendix plays an important role in colorectal immunity and the homeostasis of the gut microbiome. We aimed to evaluate the prognostic value of prior appendectomy for patients with colorectal cancer (CRC). This study revealed that prior appendectomy is an independent risk factor for the prognosis of patients with CRC, based on a multicentral CRC cohort. We further demonstrated that appendectomy induced a poor prognosis of CRC through the depletion of M1 macrophage cells in AOM-induced mice, which was confirmed in age-, sex-, and location-matched patients’ cohorts and orthotopic model models with the CT26 cell line. Poor responses to anti-PD-1 immunotherapy were detected in patients with CRC with appendectomy, and cetuximab is an effective treatment for patients with appendectomy-associated colorectal cancer (APD-CRC) to improve their prognosis. Our study will provide a reference for developing treatment plans for a considerable number of patients with APD-CRC, which is of great clinical significance.

1 July 2012 in Applied Surface Science
Verified
Journal Article
Closed access
BDBin Du
Bin Du
XZXuan Zhang
Xuan Zhang
LLLan-Lan Lou
Lan-Lan Lou
YDYanling Dong
Yanling Dong
GLGaixia Liu
Gaixia Liu
SLShuangxi Liu
Shuangxi Liu

2 July 2024 in Cancer Letters
Verified
Journal Article
Open access
CHChenhao Hu
Chenhao Hu
CGCosmos Liutao Guo
Cosmos Liutao Guo
HLHarry Cheuk-Hay Lau
Harry Cheuk-Hay Lau
FSFeiyu Shi
Feiyu Shi
ZZZhe Zhang
Zhe Zhang
JYJun Yu
Jun Yu
Human appendix is critical for the maintenance of intestinal homeostasis . Appendicectomy has been the optimal treatment of acute appendicitis , yet the cancer incidence after appendix removal remains unclear. In this territory-wide retrospective cohort study , adult participants who underwent appendicectomy from 2000 to 2018 were retrieved from a population database (n = 43,983), while matched reference participants were retrieved as controls (n = 85,853). After appendicectomy, the overall cancer risk was significantly increased (subdistribution hazard ratio (SHR) = 1.124) compared to the non-appendicectomy group. Appendicectomy-treated males had higher cancer risk than males without appendicectomy (SHR = 1.197), while such difference was not observed in female participants. Significant increase in cancer risk was also observed in elder participants (age >60) with appendicectomy (SHR = 1.390). Appendicectomy was positively correlated with the risk of digestive tract and respiratory cancers including colon (SHR = 1.440), pancreas (SHR = 1.930), and trachea, bronchus, and lung (SHR = 1.394). In contrast, the risk of liver cancer was markedly decreased after appendicectomy (SHR = 0.713). In conclusion, we reported the association of appendicectomy with subsequent cancer incidence. These findings highlight the potential complication after appendix removal and the necessity of post-operative management to monitor and prevent long-term adverse events.

16 May 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
GLGaixia Liu
Gaixia Liu
JZJiaqi Zhang
Jiaqi Zhang
QLQixin Li
Qixin Li
XXXinzhu Xue
Xinzhu Xue
XGXiaolong Guo
Xiaolong Guo
YCYinnan Chen
Yinnan Chen
Kirsten rat sarcoma (KRAS)-mutant colorectal cancer (CRC) is characterized by aggressive metastatic progression and profound therapeutic resistance. While direct inhibitors have emerged recently, their clinical application is often limited by rapid adaptive resistance, highlighting the urgent need to explore new therapeutic targets. Here, we identify O6-methylguanine-DNA methyltransferase (MGMT), a classical DNA repair enzyme, as a novel epigenetic facilitator of metastasis in KRAS-mutant CRC. Through integrated analyses of clinical cohorts and orthotopic metastasis models, we found that MGMT is upregulated in KRAS-mutant tumors and correlates with liver metastasis. Functionally, MGMT promotes epithelial-mesenchymal transition (EMT) and enhances metastatic capacity in vivo and in vitro. Mechanistically, we unveil a non-canonical function of MGMT in CRC: it interacts with histone H3 and reduces repressive H3K9me3 marks at the promoter of the epithelial-mesenchymal transition master regulator TWIST1, thereby activating its transcription. Importantly, we demonstrate that targeting MGMT sensitizes KRAS-mutant colorectal cancer to anti-EGFR therapy in preclinical models, providing a novel combinatorial strategy for this recalcitrant cancer subtype. Our study redefines MGMT as a multifaceted chromatin-modifying protein and establishes it as a promising therapeutic vulnerability to bypass resistance in KRAS-mutant CRC.